US20050090450A1 - Inhibitors of serine proteases, particularly HCV NS3-NS4A protease - Google Patents
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease Download PDFInfo
- Publication number
- US20050090450A1 US20050090450A1 US10/821,793 US82179304A US2005090450A1 US 20050090450 A1 US20050090450 A1 US 20050090450A1 US 82179304 A US82179304 A US 82179304A US 2005090450 A1 US2005090450 A1 US 2005090450A1
- Authority
- US
- United States
- Prior art keywords
- aliphatic
- cycloalkyl
- aryl
- heteroaryl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CC(*)(C1)C(*)(**N(C(*)(*)I=C)C2=O)C2N1C(C(*)N(*)C(C(*)N(C)*)=O)=O Chemical compound CC(*)(C1)C(*)(**N(C(*)(*)I=C)C2=O)C2N1C(C(*)N(*)C(C(*)N(C)*)=O)=O 0.000 description 21
- NYYPPZVRQXLOCV-AZHMBEHQSA-N C=CCC1CCN(C(=O)C(NC(=O)[C@@H](NC(=O)C2=NC=CN=C2)C(C)C)C(C)C)[C@@H]1C(=O)NC(CCC)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound C=CCC1CCN(C(=O)C(NC(=O)[C@@H](NC(=O)C2=NC=CN=C2)C(C)C)C(C)C)[C@@H]1C(=O)NC(CCC)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O NYYPPZVRQXLOCV-AZHMBEHQSA-N 0.000 description 4
- PSVXGWGLOSUXCY-ZGAYVVSBSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)C(NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)C(NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)(C)C)C(=O)C(=O)NC1CC1 PSVXGWGLOSUXCY-ZGAYVVSBSA-N 0.000 description 4
- HIORMPUELFWQTF-HMAXIFMYSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC2CC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC2CC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O HIORMPUELFWQTF-HMAXIFMYSA-N 0.000 description 4
- GVXJTIKOYFYNJP-GMWSOIOOSA-N C=C(C)[C@H]1CCN(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C2=NC=CN=C2)C(C)C)C(C)C)[C@@H]1C(=O)NC(CCC)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound C=C(C)[C@H]1CCN(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C2=NC=CN=C2)C(C)C)C(C)C)[C@@H]1C(=O)NC(CCC)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O GVXJTIKOYFYNJP-GMWSOIOOSA-N 0.000 description 3
- NYYPPZVRQXLOCV-YXLDSDEYSA-N C=CCC1CCN(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C2=NC=CN=C2)C(C)C)C(C)C)[C@@H]1C(=O)NC(CCC)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound C=CCC1CCN(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C2=NC=CN=C2)C(C)C)C(C)C)[C@@H]1C(=O)NC(CCC)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O NYYPPZVRQXLOCV-YXLDSDEYSA-N 0.000 description 3
- YAJCEHYUNAGVAM-YXLDSDEYSA-N CCCC(NC(=O)[C@@H]1C(CCC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1C(CCC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O YAJCEHYUNAGVAM-YXLDSDEYSA-N 0.000 description 3
- XKPLZODIJRNLTH-QKTKDURMSA-N CCCC(NC(=O)[C@@H]1[C@@H](C(=O)N2CCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](C(=O)N2CCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O XKPLZODIJRNLTH-QKTKDURMSA-N 0.000 description 3
- OMZOSIDRSAKTBR-PNNSYDRWSA-N CCCC(NC(=O)[C@@H]1[C@@H](C(C)CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](C(C)CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O OMZOSIDRSAKTBR-PNNSYDRWSA-N 0.000 description 3
- NUVCOLXQZZPSKE-QQGSLXIVSA-N CCCC(NC(=O)[C@@H]1[C@@H](C(C)CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](C(C)CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)C)C(=O)C(=O)NC1CC1 NUVCOLXQZZPSKE-QQGSLXIVSA-N 0.000 description 3
- RLYJNXWTDNHHKY-RSGZEEEXSA-N CCCC(NC(=O)[C@@H]1[C@@H](C)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](C)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O RLYJNXWTDNHHKY-RSGZEEEXSA-N 0.000 description 3
- ABQRIGMQSHKROZ-YZFRJGDMSA-N CCCC(NC(=O)[C@@H]1[C@@H](C2=CC=CC=C2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](C2=CC=CC=C2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O ABQRIGMQSHKROZ-YZFRJGDMSA-N 0.000 description 3
- XDQVYXZGBUBPOW-HVYBWBFFSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C)C(=O)C(=O)NC1CC1 XDQVYXZGBUBPOW-HVYBWBFFSA-N 0.000 description 3
- LOTDKEZEOWJDAT-ONDVBNBYSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O LOTDKEZEOWJDAT-ONDVBNBYSA-N 0.000 description 3
- JVBHJUBYSAMBOP-DURUQFEUSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C1CCCCC1)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C1CCCCC1)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O JVBHJUBYSAMBOP-DURUQFEUSA-N 0.000 description 3
- DNWNPCHCEZTTOT-LJOKWILZSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)C)C(=O)C(=O)N[C@@H](C)C1=CC=CC=C1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)C)C(=O)C(=O)N[C@@H](C)C1=CC=CC=C1 DNWNPCHCEZTTOT-LJOKWILZSA-N 0.000 description 3
- GUQVDVQFFMVLTR-CJHDSYBLSA-N CCC[C@H](NC(=O)[C@@H]1[C@@H](C2CCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCC[C@H](NC(=O)[C@@H]1[C@@H](C2CCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 GUQVDVQFFMVLTR-CJHDSYBLSA-N 0.000 description 3
- ICJLNCSZNWUUKO-OTKSFNJNSA-N CCC[C@H](NC(=O)[C@@H]1[C@@H](CC)[C@@H](C)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCC[C@H](NC(=O)[C@@H]1[C@@H](CC)[C@@H](C)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 ICJLNCSZNWUUKO-OTKSFNJNSA-N 0.000 description 3
- UMOLPZGDGHQSJB-KMOKEHCOSA-N CCC[C@H](NC(=O)[C@@H]1[C@@H](CC2=CC=CC=C2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCC[C@H](NC(=O)[C@@H]1[C@@H](CC2=CC=CC=C2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 UMOLPZGDGHQSJB-KMOKEHCOSA-N 0.000 description 3
- NOMFEMPTOKGVAW-UHFFFAOYSA-N C=CCC(C)(C)C.CC.CC.CC(C)(C)C(C)(C)C.CC(C)(C)C1CCCC1.CC(C)(C)C1CCCCC1.CC(C)(C)CC(C)(C)C.CC(C)C(C)(C)C.CCC(C)(C)C.CCC(C)C(C)(C)C.CCC(CC)C(C)(C)C.CCCC1=CC=CC=C1 Chemical compound C=CCC(C)(C)C.CC.CC.CC(C)(C)C(C)(C)C.CC(C)(C)C1CCCC1.CC(C)(C)C1CCCCC1.CC(C)(C)CC(C)(C)C.CC(C)C(C)(C)C.CCC(C)(C)C.CCC(C)C(C)(C)C.CCC(CC)C(C)(C)C.CCCC1=CC=CC=C1 NOMFEMPTOKGVAW-UHFFFAOYSA-N 0.000 description 2
- BSFUFZZWOKAKNI-RQDTZXEHSA-N C=C[C@H]1CCN(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C2=CN=CC=N2)C(C)C)C(C)C)[C@@H]1C(=O)NC(CCC)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound C=C[C@H]1CCN(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C2=CN=CC=N2)C(C)C)C(C)C)[C@@H]1C(=O)NC(CCC)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O BSFUFZZWOKAKNI-RQDTZXEHSA-N 0.000 description 2
- VACLFQFHSRCNGS-UHFFFAOYSA-N CC(C)(C)C(C)(C)C.CC(C)(C)C1CCCC1.CC(C)(C)C1CCCCC1.CC(C)(C)CC(C)(C)C.CC(C)C(C)(C)C.CC1=CC=CC=C1CC(C)(C)C.CCC(C)C(C)(C)C Chemical compound CC(C)(C)C(C)(C)C.CC(C)(C)C1CCCC1.CC(C)(C)C1CCCCC1.CC(C)(C)CC(C)(C)C.CC(C)C(C)(C)C.CC1=CC=CC=C1CC(C)(C)C.CCC(C)C(C)(C)C VACLFQFHSRCNGS-UHFFFAOYSA-N 0.000 description 2
- ZCIZRUAGZJNKQR-UHFFFAOYSA-N CC(C)(C)C(C)(C)C.CC(C)(C)C1CCCC1.CC(C)(C)C1CCCCC1.CC(C)(C)CC(C)(C)C.CC(C)C(C)(C)C.CCC(C)C(C)(C)C Chemical compound CC(C)(C)C(C)(C)C.CC(C)(C)C1CCCC1.CC(C)(C)C1CCCCC1.CC(C)(C)CC(C)(C)C.CC(C)C(C)(C)C.CCC(C)C(C)(C)C ZCIZRUAGZJNKQR-UHFFFAOYSA-N 0.000 description 2
- KYKLTDFRWRWOFK-UHFFFAOYSA-N CC(C)(C)C(C)(C)C.CC(C)(C)C1CCCCC1.CC(C)(C)CC(C)(C)C.CC(C)C(C)(C)C.CCC(C)C(C)(C)C Chemical compound CC(C)(C)C(C)(C)C.CC(C)(C)C1CCCCC1.CC(C)(C)CC(C)(C)C.CC(C)C(C)(C)C.CCC(C)C(C)(C)C KYKLTDFRWRWOFK-UHFFFAOYSA-N 0.000 description 2
- CJLIXUHUOBMPDH-UHFFFAOYSA-N CC(C)(C)C(C)(C)C.CC(C)(C)C1CCCCC1.CC(C)C(C)(C)C.CCC(C)C(C)(C)C Chemical compound CC(C)(C)C(C)(C)C.CC(C)(C)C1CCCCC1.CC(C)C(C)(C)C.CCC(C)C(C)(C)C CJLIXUHUOBMPDH-UHFFFAOYSA-N 0.000 description 2
- YPBIIPRNZGHDDU-UHFFFAOYSA-N CC(C)(C)C(C)(C)C.CC(C)C(C)(C)C Chemical compound CC(C)(C)C(C)(C)C.CC(C)C(C)(C)C YPBIIPRNZGHDDU-UHFFFAOYSA-N 0.000 description 2
- PTMMQJRRPGTVCL-UHFFFAOYSA-N CC(C)(C)C1=NC=CN=C1.[H]N1C(=O)C=CC=C1C(C)(C)C.[H]N1C(=O)CC(=O)C=C1C(C)(C)C.[H]N1C(=O)CC(=O)CC1C(C)(C)C.[H]N1C(=O)CC(=O)NC1C(C)(C)C.[H]N1C(=O)CCC1C(C)(C)C.[H]N1C(=O)CCCC1C(C)(C)C.[H]N1C(=O)NCC1C(C)(C)C.[H]N1C(=O)OCC1C(C)(C)C.[H]N1C(=O)SCC1C(C)(C)C.[H]N1C(C(C)(C)C)=CC(Cl)=C1Cl.[H]N1C(C(C)(C)C)CNS1(=O)=O.[H]N1C(C(C)(C)C)CNS1=O.[H]N1C(C)=C(C)C(C(C)=O)=C1C(C)(C)C.[H]N1C=CC=C1C(C)(C)C.[H]N1C=CN=C1C(C)(C)C.[H]N1N=CC=C1C(C)(C)C.[H]N1N=NN=C1C(C)(C)C Chemical compound CC(C)(C)C1=NC=CN=C1.[H]N1C(=O)C=CC=C1C(C)(C)C.[H]N1C(=O)CC(=O)C=C1C(C)(C)C.[H]N1C(=O)CC(=O)CC1C(C)(C)C.[H]N1C(=O)CC(=O)NC1C(C)(C)C.[H]N1C(=O)CCC1C(C)(C)C.[H]N1C(=O)CCCC1C(C)(C)C.[H]N1C(=O)NCC1C(C)(C)C.[H]N1C(=O)OCC1C(C)(C)C.[H]N1C(=O)SCC1C(C)(C)C.[H]N1C(C(C)(C)C)=CC(Cl)=C1Cl.[H]N1C(C(C)(C)C)CNS1(=O)=O.[H]N1C(C(C)(C)C)CNS1=O.[H]N1C(C)=C(C)C(C(C)=O)=C1C(C)(C)C.[H]N1C=CC=C1C(C)(C)C.[H]N1C=CN=C1C(C)(C)C.[H]N1N=CC=C1C(C)(C)C.[H]N1N=NN=C1C(C)(C)C PTMMQJRRPGTVCL-UHFFFAOYSA-N 0.000 description 2
- KTLDUERBKUWRMC-UHFFFAOYSA-N CC(C)(C)C1=NC=CN=C1.[H]N1C(C)=C(C)C(C(C)=O)=C1C(C)(C)C Chemical compound CC(C)(C)C1=NC=CN=C1.[H]N1C(C)=C(C)C(C(C)=O)=C1C(C)(C)C KTLDUERBKUWRMC-UHFFFAOYSA-N 0.000 description 2
- YXBRCKBDKFMDBL-UHFFFAOYSA-N CC(C)(C)C1CCCCC1.CC(C)C(C)(C)C.CCC(C)(C)C.CCC(C)C(C)(C)C Chemical compound CC(C)(C)C1CCCCC1.CC(C)C(C)(C)C.CCC(C)(C)C.CCC(C)C(C)(C)C YXBRCKBDKFMDBL-UHFFFAOYSA-N 0.000 description 2
- PDAMXTFQZOIJGZ-UHFFFAOYSA-N CC(C)(C)NC1CC1 Chemical compound CC(C)(C)NC1CC1 PDAMXTFQZOIJGZ-UHFFFAOYSA-N 0.000 description 2
- UFKIBTHCRFNKDO-QXIUDNPYSA-N CCC(NC(=O)C1N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C2=NC=CN=C2)C(C)C)C(C)C)CCC1(C)C)C(=O)C(=O)N[C@@H](C)C1=CC=CC=C1 Chemical compound CCC(NC(=O)C1N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C2=NC=CN=C2)C(C)C)C(C)C)CCC1(C)C)C(=O)C(=O)N[C@@H](C)C1=CC=CC=C1 UFKIBTHCRFNKDO-QXIUDNPYSA-N 0.000 description 2
- SWTTXQMAKHFFRL-MRPNNHIHSA-N CCC(NC(=O)[C@@H]1[C@@H](C)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)NCC1=CC=CC=C1 Chemical compound CCC(NC(=O)[C@@H]1[C@@H](C)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)NCC1=CC=CC=C1 SWTTXQMAKHFFRL-MRPNNHIHSA-N 0.000 description 2
- SSTPNIFAXADXPJ-RHXZNQHASA-N CCC(NC(=O)[C@@H]1[C@@H](C)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](C)C1=CC=CC=C1 Chemical compound CCC(NC(=O)[C@@H]1[C@@H](C)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](C)C1=CC=CC=C1 SSTPNIFAXADXPJ-RHXZNQHASA-N 0.000 description 2
- AGKMNHYHUYTSNH-UVUZPMLGSA-N CCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](C)C1=CC=CC=C1 Chemical compound CCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](C)C1=CC=CC=C1 AGKMNHYHUYTSNH-UVUZPMLGSA-N 0.000 description 2
- RWFBOGQBJNLBFH-JRTNRUGJSA-N CCCC(C(C(N[C@@H](Cc1ccccc1)C(O)=O)=O)=O)NC([C@H]([C@@H](CC)CC1)N1C([C@H](C1CCCCC1)NC([C@H](C)NC(c1nccnc1)=O)=O)=O)=O Chemical compound CCCC(C(C(N[C@@H](Cc1ccccc1)C(O)=O)=O)=O)NC([C@H]([C@@H](CC)CC1)N1C([C@H](C1CCCCC1)NC([C@H](C)NC(c1nccnc1)=O)=O)=O)=O RWFBOGQBJNLBFH-JRTNRUGJSA-N 0.000 description 2
- GWDFBWKTLSVHSN-HRURTOGHSA-N CCCC(NC(=O)[C@@H]1C(C2=CC=CC=C2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C(C)C)C(C)C)C(=O)C(=O)NCC(=O)O Chemical compound CCCC(NC(=O)[C@@H]1C(C2=CC=CC=C2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C(C)C)C(C)C)C(=O)C(=O)NCC(=O)O GWDFBWKTLSVHSN-HRURTOGHSA-N 0.000 description 2
- KCFXWOYQLZTMDL-SJRGXVGTSA-N CCCC(NC(=O)[C@@H]1C(C2CC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCCC(NC(=O)[C@@H]1C(C2CC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)C)C(=O)C(=O)NC1CC1 KCFXWOYQLZTMDL-SJRGXVGTSA-N 0.000 description 2
- OFCKEZCPNOZAFK-AOHJNTACSA-N CCCC(NC(=O)[C@@H]1C(CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1C(CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O OFCKEZCPNOZAFK-AOHJNTACSA-N 0.000 description 2
- BRGULITUIWTZFU-CCNKPHAVSA-N CCCC(NC(=O)[C@@H]1C(CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)OC(C)(C)C Chemical compound CCCC(NC(=O)[C@@H]1C(CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)OC(C)(C)C BRGULITUIWTZFU-CCNKPHAVSA-N 0.000 description 2
- YAJCEHYUNAGVAM-AZHMBEHQSA-N CCCC(NC(=O)[C@@H]1C(CCC)CCN1C(=O)C(NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1C(CCC)CCN1C(=O)C(NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O YAJCEHYUNAGVAM-AZHMBEHQSA-N 0.000 description 2
- OKEVICUKKIBVIJ-RQDTZXEHSA-N CCCC(NC(=O)[C@@H]1[C@@H](C(=O)N(C)C)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](C(=O)N(C)C)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O OKEVICUKKIBVIJ-RQDTZXEHSA-N 0.000 description 2
- BCAKVHUGWWERSX-QKTKDURMSA-N CCCC(NC(=O)[C@@H]1[C@@H](C(=O)N2CCOCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](C(=O)N2CCOCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O BCAKVHUGWWERSX-QKTKDURMSA-N 0.000 description 2
- MDZUSCMSYNKTDC-FJMZJMRHSA-N CCCC(NC(=O)[C@@H]1[C@@H](C(=O)OC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](C(=O)OC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O MDZUSCMSYNKTDC-FJMZJMRHSA-N 0.000 description 2
- YRSTXUPQJATYDJ-RQDTZXEHSA-N CCCC(NC(=O)[C@@H]1[C@@H](C(C)(C)Br)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](C(C)(C)Br)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O YRSTXUPQJATYDJ-RQDTZXEHSA-N 0.000 description 2
- WJHOUKJNAGITGG-FERRTZGBSA-N CCCC(NC(=O)[C@@H]1[C@@H](C(C)CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](C(C)CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 WJHOUKJNAGITGG-FERRTZGBSA-N 0.000 description 2
- SUZRMGUAVTYYNC-YZWWVZNVSA-N CCCC(NC(=O)[C@@H]1[C@@H](C2CCCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](C2CCCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 SUZRMGUAVTYYNC-YZWWVZNVSA-N 0.000 description 2
- ILASMXSDFXPAII-RUTNTBAOSA-N CCCC(NC(=O)[C@@H]1[C@@H](C2CCCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)N[C@@H](C)C1=CC=CC=C1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](C2CCCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)N[C@@H](C)C1=CC=CC=C1 ILASMXSDFXPAII-RUTNTBAOSA-N 0.000 description 2
- UHKJQCPGJILSLW-NLZLNYBNSA-N CCCC(NC(=O)[C@@H]1[C@@H](C2CCCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](C2CCCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)C)C(=O)C(=O)NC1CC1 UHKJQCPGJILSLW-NLZLNYBNSA-N 0.000 description 2
- SRJFQDXCNGZRIC-GOWUBMLNSA-N CCCC(NC(=O)[C@@H]1[C@@H](C2CCCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1CSC(=O)N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)N[C@@H](C)C1=CC=CC=C1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](C2CCCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1CSC(=O)N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)N[C@@H](C)C1=CC=CC=C1 SRJFQDXCNGZRIC-GOWUBMLNSA-N 0.000 description 2
- OZRYJMTZMYICJW-MZQQPIFJSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C(C)C)C(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C(C)C)C(C)C)C(=O)C(=O)NC1CC1 OZRYJMTZMYICJW-MZQQPIFJSA-N 0.000 description 2
- YNRXCTRWTYZCGH-IDIGWYQPSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN1)C1CCCCC1)C(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN1)C1CCCCC1)C(C)C)C(=O)C(=O)NC1CC1 YNRXCTRWTYZCGH-IDIGWYQPSA-N 0.000 description 2
- VXHVRDZYZSVUQA-FJMZJMRHSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)=O)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)=O)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O VXHVRDZYZSVUQA-FJMZJMRHSA-N 0.000 description 2
- LTOGVCJVIDTEPX-JPQQJXNESA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)CC)C(=O)C(=O)NC1CC1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)CC)C(=O)C(=O)NC1CC1 LTOGVCJVIDTEPX-JPQQJXNESA-N 0.000 description 2
- ULVLCZSVJHPELE-LXNLVVODSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)CC)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)CC)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O ULVLCZSVJHPELE-LXNLVVODSA-N 0.000 description 2
- FLVFIPDVFCZVOQ-IVEQDWAVSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)[C@@H](C)OC)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)[C@@H](C)OC)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O FLVFIPDVFCZVOQ-IVEQDWAVSA-N 0.000 description 2
- KXSUEVZJKJUXKE-XUQIBMNCSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)[C@@H](C)OCC)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)[C@@H](C)OCC)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O KXSUEVZJKJUXKE-XUQIBMNCSA-N 0.000 description 2
- FLVFIPDVFCZVOQ-SVGVRTHTSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)[C@H](C)OC)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)[C@H](C)OC)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O FLVFIPDVFCZVOQ-SVGVRTHTSA-N 0.000 description 2
- OOIFBPIGXDQMTQ-BUCDTFABSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 OOIFBPIGXDQMTQ-BUCDTFABSA-N 0.000 description 2
- HMMOZIZTMZCOME-FFXBHBOCSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)N[C@@H](C)C1=CC=CC=C1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)N[C@@H](C)C1=CC=CC=C1 HMMOZIZTMZCOME-FFXBHBOCSA-N 0.000 description 2
- QSBCONJZSKBJLK-CXFUWRPKSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O QSBCONJZSKBJLK-CXFUWRPKSA-N 0.000 description 2
- JBQAVTUXSRPFQN-ICMUEKKJSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)C)C(=O)C(=O)NC1CC1 JBQAVTUXSRPFQN-ICMUEKKJSA-N 0.000 description 2
- RGPFNOMXFLOXIY-DURUQFEUSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O RGPFNOMXFLOXIY-DURUQFEUSA-N 0.000 description 2
- HGJBDTXBBALSFP-MKOOAKQSSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)CC)C(=O)C(=O)NC1CC1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)CC)C(=O)C(=O)NC1CC1 HGJBDTXBBALSFP-MKOOAKQSSA-N 0.000 description 2
- LDOHTYHFISGWOV-DNCFUMQYSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)CC)C(=O)C(=O)N[C@@H](C)C1=CC=CC=C1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)CC)C(=O)C(=O)N[C@@H](C)C1=CC=CC=C1 LDOHTYHFISGWOV-DNCFUMQYSA-N 0.000 description 2
- XSYAFKBJXDEJTH-MHRUMEFDSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)CC)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)CC)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O XSYAFKBJXDEJTH-MHRUMEFDSA-N 0.000 description 2
- UGCWWJJAZXYHLK-MJAZKTBNSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C1CCCCC1)C(=O)C(=O)NC1CC1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C1CCCCC1)C(=O)C(=O)NC1CC1 UGCWWJJAZXYHLK-MJAZKTBNSA-N 0.000 description 2
- JREFNRIYWZLYHE-ISWDELSZSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C1CCCCC1)C(=O)C(=O)N[C@@H](C)C1=CC=CC=C1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C1CCCCC1)C(=O)C(=O)N[C@@H](C)C1=CC=CC=C1 JREFNRIYWZLYHE-ISWDELSZSA-N 0.000 description 2
- RYSWBHFABLQQRS-XSWMCYGDSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C1CCCCC1)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C1CCCCC1)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O RYSWBHFABLQQRS-XSWMCYGDSA-N 0.000 description 2
- XGLWELHILHSTIN-YMVVVURPSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@H](CC(C)(C)C)NC(=O)C1=CN=CC=N1)C1CCCCC1)C(=O)C(=O)NC1CC1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@H](CC(C)(C)C)NC(=O)C1=CN=CC=N1)C1CCCCC1)C(=O)C(=O)NC1CC1 XGLWELHILHSTIN-YMVVVURPSA-N 0.000 description 2
- OGSZOCJSJBGGBX-XDDLNFRPSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)C1=NC=CN=C1)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)C1=NC=CN=C1)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O OGSZOCJSJBGGBX-XDDLNFRPSA-N 0.000 description 2
- SOKKLKGGMIVXTJ-MKFPHXOISA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@H](CC1=C(C)C=CC=C1)NC(=O)C1=NC=CN=C1)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@@H](NC(=O)[C@H](CC1=C(C)C=CC=C1)NC(=O)C1=NC=CN=C1)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O SOKKLKGGMIVXTJ-MKFPHXOISA-N 0.000 description 2
- HYVQRUYLIXIYSN-AOCGXCKTSA-N CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@H](CC(C)(C)C)NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](CC)CCN1C(=O)[C@H](CC(C)(C)C)NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(=O)C(=O)NC1CC1 HYVQRUYLIXIYSN-AOCGXCKTSA-N 0.000 description 2
- MDZUSCMSYNKTDC-MUADECAGSA-N CCCC(NC(=O)[C@@H]1[C@H](C(=O)OC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@H](C(=O)OC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O MDZUSCMSYNKTDC-MUADECAGSA-N 0.000 description 2
- LJQOUJWJSMXGJR-MBFGAFETSA-N CCC[C@H](NC(=O)[C@@H]1[C@@H](C(C)(C)C)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCC[C@H](NC(=O)[C@@H]1[C@@H](C(C)(C)C)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 LJQOUJWJSMXGJR-MBFGAFETSA-N 0.000 description 2
- CRFGPIHTRNUSNI-LTKXUUQSSA-N CCC[C@H](NC(=O)[C@@H]1[C@@H](C(C)C)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCC[C@H](NC(=O)[C@@H]1[C@@H](C(C)C)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 CRFGPIHTRNUSNI-LTKXUUQSSA-N 0.000 description 2
- UIHPGBBRBPJJDB-FKLLSYGDSA-N CCC[C@H](NC(=O)[C@@H]1[C@@H](C(C)C)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCC[C@H](NC(=O)[C@@H]1[C@@H](C(C)C)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)C)C(=O)C(=O)NC1CC1 UIHPGBBRBPJJDB-FKLLSYGDSA-N 0.000 description 2
- PUDJZLHLJNWSNF-CJHDSYBLSA-N CCC[C@H](NC(=O)[C@@H]1[C@@H](C(CC)CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCC[C@H](NC(=O)[C@@H]1[C@@H](C(CC)CC)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 PUDJZLHLJNWSNF-CJHDSYBLSA-N 0.000 description 2
- YYKOVZPSEULZCR-RIYYKGKPSA-N CCC[C@H](NC(=O)[C@@H]1[C@@H](C)C(CC)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCC[C@H](NC(=O)[C@@H]1[C@@H](C)C(CC)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 YYKOVZPSEULZCR-RIYYKGKPSA-N 0.000 description 2
- REIYNCXOUSUDMG-WLCKXJJRSA-N CCC[C@H](NC(=O)[C@@H]1[C@@H](C2CCCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CC([N+](=O)[O-])=CN1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCC[C@H](NC(=O)[C@@H]1[C@@H](C2CCCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CC([N+](=O)[O-])=CN1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 REIYNCXOUSUDMG-WLCKXJJRSA-N 0.000 description 2
- RXSPRDGSUXJGBE-WLCKXJJRSA-N CCC[C@H](NC(=O)[C@@H]1[C@@H](C2CCCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CC=CN1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCC[C@H](NC(=O)[C@@H]1[C@@H](C2CCCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CC=CN1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 RXSPRDGSUXJGBE-WLCKXJJRSA-N 0.000 description 2
- SUZRMGUAVTYYNC-WLCKXJJRSA-N CCC[C@H](NC(=O)[C@@H]1[C@@H](C2CCCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCC[C@H](NC(=O)[C@@H]1[C@@H](C2CCCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 SUZRMGUAVTYYNC-WLCKXJJRSA-N 0.000 description 2
- GMLSWGSNIVWPOW-IMGJOEQVSA-N CCC[C@H](NC(=O)[C@@H]1[C@@H](C2CCCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)N[C@@H](C)C1CCCCC1 Chemical compound CCC[C@H](NC(=O)[C@@H]1[C@@H](C2CCCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=CN=CC=N1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)N[C@@H](C)C1CCCCC1 GMLSWGSNIVWPOW-IMGJOEQVSA-N 0.000 description 2
- XGXXRRPRCMMGBJ-VLLGUPHNSA-N CCC[C@H](NC(=O)[C@@H]1[C@@H](C2CCCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 Chemical compound CCC[C@H](NC(=O)[C@@H]1[C@@H](C2CCCCC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1 XGXXRRPRCMMGBJ-VLLGUPHNSA-N 0.000 description 2
- GCKBCAOWDCCUKH-RHBUBKOMSA-N CC[C@H]1CCN(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C2=NC=CN=C2)C2CCCCC2)C(C)(C)C)[C@@H]1C(=O)NC(CC(F)F)C(=O)C(=O)NC1CC1 Chemical compound CC[C@H]1CCN(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C2=NC=CN=C2)C2CCCCC2)C(C)(C)C)[C@@H]1C(=O)NC(CC(F)F)C(=O)C(=O)NC1CC1 GCKBCAOWDCCUKH-RHBUBKOMSA-N 0.000 description 2
- UOLHPQDCWNFBBV-UHFFFAOYSA-N [H]N(C(=O)C(=O)N([H])C(C)(C)C)C1CC1.[H]N(CC(C)C)C(=O)C(=O)N([H])C(C)(C)C.[H]N(CC1=CC=CC=C1)C(=O)C(=O)N([H])C(C)(C)C Chemical compound [H]N(C(=O)C(=O)N([H])C(C)(C)C)C1CC1.[H]N(CC(C)C)C(=O)C(=O)N([H])C(C)(C)C.[H]N(CC1=CC=CC=C1)C(=O)C(=O)N([H])C(C)(C)C UOLHPQDCWNFBBV-UHFFFAOYSA-N 0.000 description 2
- BAOQVHPLBCBFDW-WITCLMPNSA-N [H]N1C=CN=C1C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CC[C@H](C(C)C)[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1 Chemical compound [H]N1C=CN=C1C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CC[C@H](C(C)C)[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1 BAOQVHPLBCBFDW-WITCLMPNSA-N 0.000 description 2
- DVDOGDFEWPGXFT-SMMICIOOSA-N *.*.B.C.C.C=CC[C@H]1CCN(C(=O)OC(C)(C)C)[C@@H]1C(=O)OC.CC(C)[C@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(=O)O.CCC[C@H](NC(=O)[C@@H]1[C@@H](CC2CC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O.COC(=O)[C@@H]1[C@@H](CC2CC2)CCN1C(=O)OC(C)(C)C.COC(=O)[C@@H]1[C@@H](CC2CC2)CCN1C(=O)OC(C)(C)C.COC(=O)[C@@H]1[C@@H](CC2CC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C Chemical compound *.*.B.C.C.C=CC[C@H]1CCN(C(=O)OC(C)(C)C)[C@@H]1C(=O)OC.CC(C)[C@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(=O)O.CCC[C@H](NC(=O)[C@@H]1[C@@H](CC2CC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O.COC(=O)[C@@H]1[C@@H](CC2CC2)CCN1C(=O)OC(C)(C)C.COC(=O)[C@@H]1[C@@H](CC2CC2)CCN1C(=O)OC(C)(C)C.COC(=O)[C@@H]1[C@@H](CC2CC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C DVDOGDFEWPGXFT-SMMICIOOSA-N 0.000 description 1
- WHYVQMFEWZMPIE-DVNNGKERSA-M C.C.C.CC(C)(C)OC(=O)[C@@H]1[C@@H](C(=O)N2CCOCC2)CCN1C(=O)OCC1=CC=CC=C1.CC(C)(C)OC(=O)[C@@H]1[C@@H](C(=O)O)CCN1C(=O)OCC1=CC=CC=C1.COC(=O)[C@H]1CCN(C(=O)OCC2=CC=CC=C2)[C@@H]1C(=O)OC(C)(C)C.I.[HH].[Li]O Chemical compound C.C.C.CC(C)(C)OC(=O)[C@@H]1[C@@H](C(=O)N2CCOCC2)CCN1C(=O)OCC1=CC=CC=C1.CC(C)(C)OC(=O)[C@@H]1[C@@H](C(=O)O)CCN1C(=O)OCC1=CC=CC=C1.COC(=O)[C@H]1CCN(C(=O)OCC2=CC=CC=C2)[C@@H]1C(=O)OC(C)(C)C.I.[HH].[Li]O WHYVQMFEWZMPIE-DVNNGKERSA-M 0.000 description 1
- DSZROTTXNZYIGB-LDZLTUNMSA-N C.C.C=C[C@H]1CCN(C(=O)OC(C)(C)C)[C@@H]1C(=O)OC.CC(C)[C@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(=O)N1CC[C@H](C2CC2)[C@H]1C(=O)OC(C)(C)C.CCC[C@H](NC(=O)[C@@H]1[C@@H](C2CC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)C)C(=O)C(=O)NC1CC1.F Chemical compound C.C.C=C[C@H]1CCN(C(=O)OC(C)(C)C)[C@@H]1C(=O)OC.CC(C)[C@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(=O)N1CC[C@H](C2CC2)[C@H]1C(=O)OC(C)(C)C.CCC[C@H](NC(=O)[C@@H]1[C@@H](C2CC2)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)C)C(=O)C(=O)NC1CC1.F DSZROTTXNZYIGB-LDZLTUNMSA-N 0.000 description 1
- DGOALCOYTYQAQZ-UHFFFAOYSA-N C.C=CCC1CCN(C(C)(C)C)C1C(C)(C)C.CC(C)(C)C1C(C2CCCCC2)CCN1C(C)(C)C.CC(C)(C)C1CC(C2=CC=CC=C2)CN1C(C)(C)C.CC(C)(C)C1CC(O/C2=C/C(C3=CSC=N3)=N\C3=C2C=CC=C3)CN1C(C)(C)C.CC(C)(C)C1CC(O/C2=N/C(C3=CC=CC=C3)=N\C3=C2C=CC=C3)CN1C(C)(C)C.CC(C)C1CCN(C(C)(C)C)C1C(C)(C)C.CC1CCN(C(C)(C)C)C1C(C)(C)C.CC1CN(C(C)(C)C)C(C(C)(C)C)C1C.CCC(C)C1CCN(C(C)(C)C)C1C(C)(C)C.CCC1CCN(C(C)(C)C)C1C(C)(C)C.CCC1CN(C(C)(C)C)C(C(C)C)C1C Chemical compound C.C=CCC1CCN(C(C)(C)C)C1C(C)(C)C.CC(C)(C)C1C(C2CCCCC2)CCN1C(C)(C)C.CC(C)(C)C1CC(C2=CC=CC=C2)CN1C(C)(C)C.CC(C)(C)C1CC(O/C2=C/C(C3=CSC=N3)=N\C3=C2C=CC=C3)CN1C(C)(C)C.CC(C)(C)C1CC(O/C2=N/C(C3=CC=CC=C3)=N\C3=C2C=CC=C3)CN1C(C)(C)C.CC(C)C1CCN(C(C)(C)C)C1C(C)(C)C.CC1CCN(C(C)(C)C)C1C(C)(C)C.CC1CN(C(C)(C)C)C(C(C)(C)C)C1C.CCC(C)C1CCN(C(C)(C)C)C1C(C)(C)C.CCC1CCN(C(C)(C)C)C1C(C)(C)C.CCC1CN(C(C)(C)C)C(C(C)C)C1C DGOALCOYTYQAQZ-UHFFFAOYSA-N 0.000 description 1
- IJAUQBOIUHKWOW-UHFFFAOYSA-N C=CC1CC1(C)C.CC1(C)CC1C1CC1.CC1CC1(C)C.CCC1CC1(C)C.CCCC(C)(C)C.CCCC(C)(C)CC.CCCC(C)(C)CCC Chemical compound C=CC1CC1(C)C.CC1(C)CC1C1CC1.CC1CC1(C)C.CCC1CC1(C)C.CCCC(C)(C)C.CCCC(C)(C)CC.CCCC(C)(C)CCC IJAUQBOIUHKWOW-UHFFFAOYSA-N 0.000 description 1
- JJEVZPSQCYQOMG-UHFFFAOYSA-N CC(C)(C)C1CC(O/C2=C/C(C(F)(F)F)=N\C3=C2C=CC=C3C(F)(F)F)CN1C(C)(C)C.CC(C)(C)C1CC(O/C2=C/C=C\C3=C2C=CN=C3)CN1C(C)(C)C.CC(C)(C)C1CC(O/C2=C/C=N\C3=C2C=CC(C(F)(F)F)=C3)CN1C(C)(C)C.CC(C)(C)C1CC(O/C2=C/C=N\C3=C2C=CC(Cl)=C3)CN1C(C)(C)C.CC(C)(C)C1CC(O/C2=N/C(N3C=CN=C3)=N\C3=C2C=CC=C3)CN1C(C)(C)C.COC1=CC2=C(C=C1)/C(OC1CC(C(C)(C)C)N(C(C)(C)C)C1)=C\C(N)=N/2.COC1=CC2=C(C=C1)/C(OC1CC(C(C)(C)C)N(C(C)(C)C)C1)=C\C=N/2.COC1=CC2=C(C=C1OC)/C(OC1CC(C(C)(C)C)N(C(C)(C)C)C1)=N\C(N1CCOCC1)=N/2 Chemical compound CC(C)(C)C1CC(O/C2=C/C(C(F)(F)F)=N\C3=C2C=CC=C3C(F)(F)F)CN1C(C)(C)C.CC(C)(C)C1CC(O/C2=C/C=C\C3=C2C=CN=C3)CN1C(C)(C)C.CC(C)(C)C1CC(O/C2=C/C=N\C3=C2C=CC(C(F)(F)F)=C3)CN1C(C)(C)C.CC(C)(C)C1CC(O/C2=C/C=N\C3=C2C=CC(Cl)=C3)CN1C(C)(C)C.CC(C)(C)C1CC(O/C2=N/C(N3C=CN=C3)=N\C3=C2C=CC=C3)CN1C(C)(C)C.COC1=CC2=C(C=C1)/C(OC1CC(C(C)(C)C)N(C(C)(C)C)C1)=C\C(N)=N/2.COC1=CC2=C(C=C1)/C(OC1CC(C(C)(C)C)N(C(C)(C)C)C1)=C\C=N/2.COC1=CC2=C(C=C1OC)/C(OC1CC(C(C)(C)C)N(C(C)(C)C)C1)=N\C(N1CCOCC1)=N/2 JJEVZPSQCYQOMG-UHFFFAOYSA-N 0.000 description 1
- HXXXIFIQOYAVJW-UHFFFAOYSA-N CC(C)(C)C1CC(O/C2=C/C=N\C3=C2C=CC=C3)CN1C(C)(C)C.CC(C)(C)C1CC(O/C2=C/N=C\C3=C2C=CC=C3)CN1C(C)(C)C.CC(C)(C)C1CC(O/C2=N/C=C\C3=C2C=CC=C3)CN1C(C)(C)C.CC(C)(C)C1CC(OC(=O)C2=CC3=C(C=CC=C3)C=C2)CN1C(C)(C)C.CC(C)(C)C1CC(OC(=O)N2CCC3=C(C=CC=C3)C2)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=C3/C=C\C=C/C3=CC=C2)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=C3C=CC=CC3=NC=N2)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=CC3=C(C=CC=C3)C=C2)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=CC=C(Cl)C=N2)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=CC=CC=C2)CN1C(C)(C)C Chemical compound CC(C)(C)C1CC(O/C2=C/C=N\C3=C2C=CC=C3)CN1C(C)(C)C.CC(C)(C)C1CC(O/C2=C/N=C\C3=C2C=CC=C3)CN1C(C)(C)C.CC(C)(C)C1CC(O/C2=N/C=C\C3=C2C=CC=C3)CN1C(C)(C)C.CC(C)(C)C1CC(OC(=O)C2=CC3=C(C=CC=C3)C=C2)CN1C(C)(C)C.CC(C)(C)C1CC(OC(=O)N2CCC3=C(C=CC=C3)C2)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=C3/C=C\C=C/C3=CC=C2)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=C3C=CC=CC3=NC=N2)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=CC3=C(C=CC=C3)C=C2)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=CC=C(Cl)C=N2)CN1C(C)(C)C.CC(C)(C)C1CC(OC2=CC=CC=C2)CN1C(C)(C)C HXXXIFIQOYAVJW-UHFFFAOYSA-N 0.000 description 1
- FIZUILACDXTDCK-YGXNMDBFSA-N CCCC(C(C(NC1CC1)=O)=O)NC([C@H]([C@@H](CC)CC1)N1C([C@H](C(C)C)NC([C@H](C)NC(c1ncc[nH]1)=O)=O)=O)=O Chemical compound CCCC(C(C(NC1CC1)=O)=O)NC([C@H]([C@@H](CC)CC1)N1C([C@H](C(C)C)NC([C@H](C)NC(c1ncc[nH]1)=O)=O)=O)=O FIZUILACDXTDCK-YGXNMDBFSA-N 0.000 description 1
- URDSIJTWJGZHLY-OQFJLMMRSA-N CCCC(NC(=O)[C@@H]1[C@@H](C(C)=O)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](C(C)=O)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O URDSIJTWJGZHLY-OQFJLMMRSA-N 0.000 description 1
- SZPYJWDOCLNOTG-GMWSOIOOSA-N CCCC(NC(=O)[C@@H]1[C@@H](C(C)C)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound CCCC(NC(=O)[C@@H]1[C@@H](C(C)C)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O SZPYJWDOCLNOTG-GMWSOIOOSA-N 0.000 description 1
- XTNGNDLWDCSEPU-LXRFFTKZSA-N CCC[C@@H](C(C(NC1CC1)=O)=O)NC([C@H]([C@@H](C)CC1)N1C([C@H](C(C)(C)C)NC([C@H](C)NC(c1cc([N+]([O-])=O)c[nH]1)=O)=O)=O)=O Chemical compound CCC[C@@H](C(C(NC1CC1)=O)=O)NC([C@H]([C@@H](C)CC1)N1C([C@H](C(C)(C)C)NC([C@H](C)NC(c1cc([N+]([O-])=O)c[nH]1)=O)=O)=O)=O XTNGNDLWDCSEPU-LXRFFTKZSA-N 0.000 description 1
- KNUZOSBRWNHLBB-VIFPVBQESA-N C[C@@H](c(cc1)ccc1Cl)NC(C)(C)C Chemical compound C[C@@H](c(cc1)ccc1Cl)NC(C)(C)C KNUZOSBRWNHLBB-VIFPVBQESA-N 0.000 description 1
- CYGQLONOUWJWKG-QMMMGPOBSA-N C[C@@H](c(cc1)ccc1F)NC(C)(C)O Chemical compound C[C@@H](c(cc1)ccc1F)NC(C)(C)O CYGQLONOUWJWKG-QMMMGPOBSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents.
- the invention further relates to pharmaceutical compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection.
- the invention also relates to processes for preparing the compounds and methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
- HCV hepatitis C virus
- the HCV genome encodes a polyprotein of 3010-3033 amino acids [Q. L. Choo, et. al., “Genetic Organization and Diversity of the Hepatitis C Virus.” Proc. Natl. Acad. Sci. USA, 88, pp. 2451-2455 (1991); N. Kato et al., “Molecular Cloning of the Human Hepatitis C Virus Genome From Japanese Patients with Non-A, Non-B Hepatitis,” Proc. Natl. Acad. Sci. USA, 87, pp. 9524-9528 (1990); A. Takamizawa et. al., “Structure and Organization of the Hepatitis C Virus Genome Isolated From Human Carriers,” J.
- the HCV nonstructural (NS) proteins are presumed to provide the essential catalytic machinery for viral replication.
- the NS proteins are derived by proteolytic cleavage of the polyprotein [R. Bartenschlager et. al., “Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions,” J. Virol ., 67, pp. 3835-3844 (1993); A. Grakoui et.
- the HCV NS protein 3 contains a serine protease activity that helps process the majority of the viral enzymes, and is thus considered essential for viral replication and infectivity. It is known that mutations in the yellow fever virus NS3 protease decrease viral infectivity [Chambers, T. J. et. al., “Evidence that the N-terminal Domain of Nonstructural Protein NS3 From Yellow Fever Virus is a Serine Protease Responsible for Site-Specific Cleavages in the Viral Polyprotein”, Proc. Natl. Acad. Sci. USA, 87, pp. 8898-8902 (1990)].
- the first 181 amino acids of NS3 have been shown to contain the serine protease domain of NS3 that processes all four downstream sites of the HCV polyprotein [C. Lin et al., “Hepatitis C Virus NS3 Serine Proteinase: Trans-Cleavage Requirements and Processing Kinetics”, J. Virol., 68, pp. 8147-8157 (1994)].
- HCV NS3 serine protease and its associated cofactor, NS4A helps process all of the viral enzymes, and is thus considered essential for viral replication. This processing appears to be analogous to that carried out by the human immunodeficiency virus aspartyl protease, which is also involved in viral enzyme processing. HIV protease inhibitors, which inhibit viral protein processing, are potent antiviral agents in man, indicating that interrupting this stage of the viral life cycle results in therapeutically active agents. Consequently HCV NS3 serine protease is also an attractive target for drug discovery.
- Such inhibitors would have therapeutic potential as protease inhibitors, particularly as serine protease inhibitors, and more particularly as HCV NS3 protease inhibitors. Specifically, such compounds may be useful as antiviral agents, particularly as anti-HCV agents.
- the present invention provides a compound of formula I: or a pharmaceutically acceptable salt, or mixtures thereof, wherein:
- the invention also relates to processes for preparing the above compounds and to compositions that comprise the above compounds and the use thereof.
- Such compositions may be used to pre-treat invasive devices to be inserted into a patient, to treat biological samples, such as blood, prior to administration to a patient, and for direct administration to a patient.
- the composition will be used to inhibit HCV replication and to lessen the risk of or the severity of HCV infection.
- the present invention provides a compound of formula I: or a pharmaceutically acceptable salt, or mixtures thereof, wherein:
- aryl means a monocyclic or bicyclic carbocyclic aromatic ring system. Phenyl is an example of a monocyclic aromatic ring system. Bicyclic aromatic ring systems include systems wherein both rings are aromatic, e.g., naphthyl, and systems wherein only one of the two rings is aromatic, e.g., tetralin. It is understood that as used herein, the term “(C6-C10)-aryl-” includes any one of a C6, C7, C8, C9, and C10 monocyclic or bicyclic carbocyclic aromatic ring.
- heterocyclyl as used herein means a monocyclic or bicyclic non-aromatic ring system having 1 to 3 heteroatom or heteroatom groups in each ring selected from O, N, NH, S, SO, and SO 2 in a chemically stable arrangement.
- heterocyclyl one or both rings may contain said heteroatom or heteroatom groups.
- (C5-C10)-heterocyclyl- includes any one of a C5, C6, C7, C8, C9, and C10 monocyclic or bicyclic non-aromatic ring system having 1 to 3 heteroatom or heteroatom groups in each ring selected from O, N, NH, and S in a chemically stable arrangement.
- heteroaryl as used herein means a monocyclic or bicyclic aromatic ring system having 1 to 3 heteroatom or heteroatom groups in each ring selected from O, N, NH, and S in a chemically stable arrangement.
- heteroaryl a monocyclic or bicyclic aromatic ring system having 1 to 3 heteroatom or heteroatom groups in each ring selected from O, N, NH, and S in a chemically stable arrangement.
- aliphatic as used herein means a straight chained or branched alkyl, alkenyl or alkynyl. It is understood that as used herein, the term “(C1-C12)-aliphatic-” includes any one of a C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, and C12 straight or branched alkyl chain of carbon atoms. It is also understood that alkenyl or alkynyl embodiments need at least two carbon atoms in the aliphatic chain.
- cycloalkyl or cycloalkenyl refers to a monocyclic or fused or bridged bicyclic carbocyclic ring system that is not aromatic.
- Cycloalkenyl rings have one or more units of unsaturation. It is also understood that as used herein, the term “(C3-C10)-cycloalkyl- or -cycloalkenyl-” includes any one of a C3, C4, C5, C6, C7, C8, C9, and C10 monocyclic or fused or bridged bicyclic carbocyclic ring. Preferred cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, nornbornyl, adamantyl and decalin-yl.
- chemically stable arrangement refers to a compound structure that renders the compound sufficiently stable to allow manufacture and administration to a mammal by methods known in the art. Typically, such compounds are stable at a temperature of 40° C. or less, in the absence of moisture or other chemically reactive condition, for at least a week.
- the radical is, wherein;
- R 9′ is
- R 9′ is
- R 9′ is ethyl
- R 9 , R 10 , and R 10′ X and Y are both a bond and Z is hydrogen; and in R 9′ ;
- Z is —O—(C1-C6)-aliphatic or —N(R′) 2 , wherein the two R′ groups bound to the nitrogen atom may optionally form a 3- to 7-membered saturated or partially unsaturated ring system wherein up to 3 ring atoms may be optionally replaced with a heteroatom independently selected from N, NH, O, S, SO, and SO 2 , wherein said ring system may be optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl, wherein any ring has up to 3 substituents selected independently from J.
- Z is —N(R′) 2 , wherein the two R′ groups bound to the nitrogen atom may optionally form a 3- to 7-membered saturated or partially unsaturated ring system wherein up to 3 ring atoms may be optionally replaced with a heteroatom independently selected from N, NH, O, S, SO, and SO 2 , wherein said ring system may be optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl, wherein any ring has up to 3 substituents selected independently from J.
- R 9 , and R 10 X and Y are both a bond and Z is hydrogen; and in each of R 9′ and R 10′ independently,
- Z in each of R 9′ and R 10′ independently, is
- each of R 9′ and R 10′ independently is (C1-C6)-aliphatic-.
- R 10 , and R 10′ X and Y are both a bond and Z is hydrogen; and in R 9 and R 9′ ;
- W is: wherein in the W, the NR 6 R 6 is selected from —NH—(C1-C6 aliphatic), —NH—(C3-C6 cycloalkyl), —NH—CH(CH 3 )-aryl, or —NH—CH(CH 3 )-heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with up to 3 halogens.
- the NR 6 R 6 is:
- the NR 6 R 6 is:
- the NR 6 R 6 is:
- the NR 6 R 6 is:
- the NR 6 R 6 in the W radical is:
- the NR 6 R 6 in the W radical is:
- the NR 6 R 6 is:
- W in compounds of formula I is: wherein R 8 is as defined above.
- each R 8 together with the boron atom is a (C5-C10)-membered heterocyclic ring having no additional heteroatoms other than the boron and the two oxygen atoms.
- W is: wherein R′ is (C1-C6)-aliphatic.
- R′ is methyl
- R 5′ is hydrogen and R 5 is:
- R 5′ is hydrogen and R 5 is:
- R 5′ and R 5 is:
- R 2 , R 4 , and R 7 are each independently H, methyl, ethyl, or propyl.
- R 2 , R 4 , and R 7 are each hydrogen.
- R 3 is:
- R 3 is:
- R 3 is:
- R 1 is:
- R 1 is:
- R 1 is isopropyl or cyclohexyl.
- the radical is: wherein:
- the radical is:
- V is —C(O)— and R is a bond.
- V is —C(O)—
- R is a bond
- T is (C5-C6)heterocyclyl- or (C5-C6)heteroaryl-;
- T is: wherein:
- T is:
- this invention does not include the following compounds:
- this invention does not include the following compounds wherein:
- this invention does not include compounds wherein:
- this invention does not include compounds wherein T is a C5-heteroaryl (e.g., compounds of formula II at page 22 of WO 03/087092).
- this invention does not include compounds wherein T is an optionally substituted pyrrole group (e.g., compounds of formula II at page 22 of WO 03/087092).
- this invention does not include compounds wherein:
- the compound is: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77
- the compounds of this invention may contain one or more asymmetric carbon atoms and thus may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included in the present invention.
- Each stereogenic carbon may be of the R or S configuration.
- the compounds of this invention have the structure and stereochemistry depicted in compounds 1-77.
- Scheme 1-6 above provide synthetic pathways for the preparation of the compounds of this invention. Many of the starting proline derivatives may be purchased commercially from chemical suppliers known to those in the art. Intermediate Al may be prepared according to the procedure described in J. Med. Chem. 39, p.2367 (1996).
- Another embodiment of this invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof.
- the compound of formula I is present in an amount effective to decrease the viral load in a sample or in a patient, wherein said virus encodes a serine protease necessary for the viral life cycle, and a pharmaceutically acceptable carrier.
- salts of the compounds of this invention are preferably derived from inorganic or organic acids and bases. Included among such acid salts are the following: acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate, cyclopentane-propionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, peroxine salt, sodium bicarbonate, sodium bicarbonate
- Base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
- the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.
- lower alkyl halides such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides
- dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates
- long chain halides such
- compositions and methods of this invention may also be modified by appending appropriate functionalities to enhance selective biological properties.
- modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
- compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
- ion exchangers alumina, aluminum stearate, lecithin
- serum proteins such as human serum albumin
- buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial g
- compositions of this invention are formulated for pharmaceutical administration to a mammal.
- compositions of this invention are formulated for pharmaceutical administration to a human being.
- compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
- parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
- the compositions are administered orally or intravenously.
- Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
- the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides.
- Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
- These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
- a long-chain alcohol diluent or dispersant such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
- Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
- Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 75 mg/kg body weight per day of the protease inhibitor compounds described herein are useful in a monotherapy for the prevention and treatment of antiviral, particularly anti-HCV mediated disease.
- the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy.
- the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
- a typical preparation will contain from about 5% to about 95% active compound (w/w). In another embodiment, such preparations contain from about 20% to about 80% active compound.
- compositions of this invention comprise a combination of a compound of formula I and one or more additional therapeutic or prophylactic agents
- both the compound and the additional agent should be present at dosage levels of between about 10 to 100% and in another embodiment between about 10 to 80% of the dosage normally administered in a monotherapy regimen.
- compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
- carriers that are commonly used include lactose and corn starch.
- Lubricating agents such as magnesium stearate, are also typically added.
- useful diluents include lactose and dried cornstarch.
- aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
- compositions of this invention may be administered in the form of suppositories for rectal administration.
- suppositories may be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
- suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
- compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
- Topical application for the lower intestinal tract may be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
- the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
- Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
- the pharmaceutical compositions may be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
- Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
- the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride.
- the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
- compositions of this invention may also be administered by nasal aerosol or inhalation.
- Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
- the pharmaceutical compositions are formulated for oral administration.
- compositions of this invention additionally comprise another agent, including a cytochrome P-450 inhibitor.
- cytochrome P-450 inhibitors include, but are not limited to, ritonavir.
- compositions of this invention additionally comprise another anti-viral agent, including an anti-HCV agent.
- anti-viral agents include, but are not limited to, immunomodulatory agents, such as ⁇ -, ⁇ -, and ⁇ -interferons, pegylated derivatized interferon- ⁇ compounds, and thymosin; other anti-viral agents, such as ribavirin, amantadine, and telbivudine; other inhibitors of hepatitis C proteases (NS2-NS3 inhibitors and NS3-NS4A inhibitors); inhibitors of other targets in the HCV life cycle, including but not limited to, helicase and polymerase inhibitors; inhibitors of internal ribosome entry; broad-spectrum viral inhibitors, such as IMPDH inhibitors (e.g., VX-497 and other IMPDH inhibitors disclosed in U.S. Pat. Nos. 5,807,876 and 6,498,178, mycophenolic acid and derivatives thereof);
- a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
- a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
- the amount of active ingredients will also depend upon the particular described compound and the presence or absence and the nature of the additional anti-viral agent in the composition.
- the invention provides a method for treating a patient infected with a virus characterized by a virally encoded serine protease that is necessary for the life cycle of the virus by administering to said patient a pharmaceutically acceptable composition of this invention.
- the methods of this invention are used to treat a patient suffering from a HCV infection. Such treatment may completely eradicate the viral infection or reduce the severity thereof.
- the methods of this invention are used to treat a patient suffering from a HCV infection wherein the patient is a human being.
- the methods of this invention additionally comprise the step of administering to said patient an anti-viral agent preferably an anti-HCV agent.
- anti-viral agents include, but are not limited to, immunomodulatory agents, such as ⁇ -, ⁇ -, and ⁇ -interferons, pegylated derivatized interferon- ⁇ compounds, and thymosin; other anti-viral agents, such as ribavirin, amantadine, and telbivudine; other inhibitors of hepatitis C proteases (NS2-NS3 inhibitors and NS3-NS4A inhibitors); inhibitors of other targets in the HCV life cycle, including helicase and polymerase inhibitors; inhibitors of internal ribosome entry; broad-spectrum viral inhibitors, such as IMPDH inhibitors (e.g., VX-497 and other IMPDH inhibitors disclosed in U.S. Pat. Nos. 5,807,876 and 6,498,178, mycophenolic acid and derivatives thereof
- Such additional agent may be administered to said patient as part of a single dosage form comprising both a compound of this invention and an additional anti-viral agent.
- the additional agent may be administered separately from the compound of this invention, as part of a multiple dosage form, wherein said additional agent is administered prior to, together with or following a composition comprising a compound of this invention.
- the present invention provides a method of pre-treating a biological substance intended for administration to a patient comprising the step of contacting said biological substance with a pharmaceutically acceptable composition comprising a compound of this invention.
- biological substances include, but are not limited to, blood and components thereof such as plasma, platelets, subpopulations of blood cells and the like; organs such as kidney, liver, heart, lung, etc; sperm and ova; bone marrow and components thereof, and other fluids to be infused into a patient such as saline, dextrose, etc.
- the invention provides methods of treating materials that may potentially come into contact with a virus characterized by a virally encoded serine protease necessary for its life cycle.
- This method comprises the step of contacting said material with a compound according to the invention.
- materials include, but are not limited to, surgical instruments and garments (e.g. clothes, gloves, aprons, gowns, masks, eyeglasses, footwear, etc.); laboratory instruments and garments (e.g. clothes, gloves, aprons, gowns, masks, eyeglasses, footwear, etc.); blood collection apparatuses and materials; and invasive devices, such as shunts, stents, etc.
- the compounds of this invention may be used as laboratory tools to aid in the isolation of a virally encoded serine protease.
- This method comprises the steps of providing a compound of this invention attached to a solid support; contacting said solid support with a sample containing a viral serine protease under conditions that cause said protease to bind to said solid support; and eluting said serine protease from said solid support.
- the viral serine protease isolated by this method is HCV NS3-NS4A protease.
- R t (min) refers to the HPLC retention time, in minutes, associated with the compound.
- the HPLC retention times listed were either obtained from the mass spec. data or using the following method:
- HCl gas was bubbled 5 minutes to a solution of 5b (3.5 g, 6.47 mmol) in 50 mL of ethyl acetate at ⁇ 20° C. Stirred at ⁇ 20° C. for 30 minutes then warmed up at rt and stirred for 1 h. It was concentrated in vacuo to 1.71 g (100%) of an oil that was reduced with 2.5 equivalent of a 1M LAH in THF solution under reflux for 4 h. Cooled and subjected to a Fieser work up which provided 1.35 g (85%) of the desired compound 8b.
- the t-butyl ester group of the capped tripeptide (410 mg, 0.688 mmol) was cleaved with a 1:1 mixture of TFA-DCM at rt for 45 minutes and concentrated in vacuo. The resulting aminoester tripeptide was coupled to hydroxyamide detailed in the next step.
- 3Phenyl proline 10a was hydrogenated with catalytic platinum oxide in ethanol/acetic acid/water (7/2/1) under 50 psi of hydrogen for 18 h to give 3-cyclohehyl proline quantitatively.
- Compound 12a was prepared according to benzoylation and esterification from example 1; step 3.
- Tripeptide C was prepared by the coupling of cyclopropylmethyl proline A (41 mg, 0.16 mmol) and capped dipeptide B (52 mg, 0.16 mmol)with EDC/HOAt to give 60 mg (77%) of the desired tripeptide C after chromatography (1:1 ethyl acetate-hexanes).
- HCV hepatitis C virus
- replicon cell monolayer was treated with a trypsin:EDTA mixture, removed, and then media A was diluted into a final concentration of 100,000 cells per ml wit. 10,000 cells in 100 ul were plated into each well of a 96-well tissue culture plate, and cultured overnight in a tissue culture incubator at 37° C.
- RNA virus such as Bovine Viral Diarrhea Virus (BVDV)
- BVDV Bovine Viral Diarrhea Virus
- RNA extraction reagents such as reagents from RNeasy kits
- Total RNA was extracted according the instruction of manufacturer with modification to improve extraction efficiency and consistency.
- total cellular RNA including HCV replicon RNA, was eluted and stored at ⁇ 80° C. until further processing.
- a Taqman real-time RT-PCR quantification assay was set up with two sets of specific primers and probe. One was for HCV and the other was for BVDV. Total RNA extractants from treated HCV replicon cells was added to the PCR reactions for quantification of both HCV and BVDV RNA in the same PCR well. Experimental failure was flagged and rejected based on the level of BVDV RNA in each well. The level of HCV RNA in each well was calculated according to a standard curve run in the same PCR plate. The percentage of inhibition or decrease of HCV RNA level due to compound treatment was calculated using the DMSO or no compound control as 0% of inhibition. The IC 50 (concentration at which 50% inhibition of HCV RNA level is observed) was calculated from the titration curve of any given compound.
- Buffer 50 mM HEPES, pH 7.8; 20% glycerol; 100 mM NaCl
- Total assay volume was 100 ⁇ L X1 conc. in ( ⁇ L) assay Buffer 86.5 see above 5 mM KK4A 0.5 25 ⁇ M 1 M DTT 0.5 5 mM DMSO or inhibitor 2.5 2.5% v/v 50 ⁇ M tNS3 0.05 25 nM 250 ⁇ M 5AB 20 25 ⁇ M (initiate)
- the buffer, KK4A, DTT, and tNS3 were combined; distributed 78 ⁇ L each into wells of 96 well plate. This was incubated at 30 C for ⁇ 5-10 min.
- test compound 2.5 uL was dissolved in DMSO (DMSO only for control) and added to each well. This was incubated at room temperature for 15 min.
- Solvent B HPLC grade acetonitrile+0.1% TFA Time Flow Max (min) % B (ml/min) press. 0 5 0.2 400 12 60 0.2 400 13 100 0.2 400 16 100 0.2 400 17 5 0.2 400
- Table 1 below depicts IC 50 data for certain ds of the invention.
- Compounds with Ki's ranging from 0.5 ⁇ M to >1 ⁇ M are designated A.
- Compounds with Ki's ranging from 0.5 ⁇ M to 0.1 ⁇ M are designated B.
- Compounds with Ki's below 0.1 ⁇ M are designated C.
- Compounds with IC 50 's ranging from 1 ⁇ M to >10 ⁇ M are designated A.
- Compounds with IC 50 's ranging from 1 ⁇ M to 0.5 ⁇ M are designated B.
- Compounds with IC 50 's below 0.5 ⁇ M are designated C.
- ND means no data.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/821,793 US20050090450A1 (en) | 2003-04-11 | 2004-04-09 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US12/169,209 US20090022688A1 (en) | 2003-04-11 | 2008-07-08 | Inhibitors of serine protease, particularly hcv ns3-ns4a protease |
US13/238,386 US8618152B2 (en) | 2003-04-11 | 2011-09-21 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/412,600 US7273885B2 (en) | 2002-04-11 | 2003-04-11 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US51376503P | 2003-10-23 | 2003-10-23 | |
US10/821,793 US20050090450A1 (en) | 2003-04-11 | 2004-04-09 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/169,209 Continuation US20090022688A1 (en) | 2003-04-11 | 2008-07-08 | Inhibitors of serine protease, particularly hcv ns3-ns4a protease |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050090450A1 true US20050090450A1 (en) | 2005-04-28 |
Family
ID=33302781
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/821,793 Abandoned US20050090450A1 (en) | 2003-04-11 | 2004-04-09 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US12/169,209 Abandoned US20090022688A1 (en) | 2003-04-11 | 2008-07-08 | Inhibitors of serine protease, particularly hcv ns3-ns4a protease |
US13/238,386 Expired - Fee Related US8618152B2 (en) | 2003-04-11 | 2011-09-21 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/169,209 Abandoned US20090022688A1 (en) | 2003-04-11 | 2008-07-08 | Inhibitors of serine protease, particularly hcv ns3-ns4a protease |
US13/238,386 Expired - Fee Related US8618152B2 (en) | 2003-04-11 | 2011-09-21 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases |
Country Status (11)
Country | Link |
---|---|
US (3) | US20050090450A1 (fr) |
EP (2) | EP2332935A1 (fr) |
JP (2) | JP2006526011A (fr) |
CN (1) | CN100453553C (fr) |
AR (1) | AR044513A1 (fr) |
AT (1) | ATE547412T1 (fr) |
AU (1) | AU2004230946A1 (fr) |
CA (1) | CA2521678A1 (fr) |
ES (1) | ES2381548T3 (fr) |
HK (1) | HK1090644A1 (fr) |
WO (1) | WO2004092162A1 (fr) |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030236242A1 (en) * | 2000-04-03 | 2003-12-25 | Robert Perni | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease |
US20050080017A1 (en) * | 2003-10-10 | 2005-04-14 | Cottrell Kevin M. | Inhibitors of serine proteases, particularly HVC NS3-NS4A protease |
US20050137139A1 (en) * | 2003-09-05 | 2005-06-23 | Perni Robert B. | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US20050197299A1 (en) * | 2000-08-31 | 2005-09-08 | Babine Robert E. | Peptidomimetic protease inhibitors |
US20050215486A1 (en) * | 2004-02-04 | 2005-09-29 | Kevin Cottrell | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US20060211629A1 (en) * | 2003-07-18 | 2006-09-21 | Britt Shawn D | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US20070161789A1 (en) * | 2003-10-10 | 2007-07-12 | Cottrell Kevin M | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US20070179167A1 (en) * | 2005-08-26 | 2007-08-02 | Cottrell Kevin M | Inhibitors of serine proteases |
US20070231262A1 (en) * | 2005-11-11 | 2007-10-04 | Vertex Pharmaceuticals, Incorporated | Hepatitis C virus variants |
WO2009003009A1 (fr) * | 2007-06-26 | 2008-12-31 | Enanta Pharmaceuticals, Inc. | Pyrrolidine substituée utilisée en tant qu'agent anti-infectieux |
US20090022689A1 (en) * | 2007-07-18 | 2009-01-22 | Yat Sun Or | C4-spiro-pyrrolidine antivirals |
US20090060874A1 (en) * | 2007-09-05 | 2009-03-05 | Yao-Ling Qiu | Bicyclic pyrrolidine derivatives |
US20090143312A1 (en) * | 1996-10-18 | 2009-06-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
WO2009099596A2 (fr) | 2008-02-04 | 2009-08-13 | Idenix Pharamaceuticals, Inc. | Inhibiteurs de sérine protéase macrocycliques |
US20090233972A1 (en) * | 2008-03-12 | 2009-09-17 | Yat Sun Or | Substituted heterocycles as anti-infectives |
US20090326019A1 (en) * | 2008-06-11 | 2009-12-31 | Yat Sun Or | 3,4-bicyclic pyrrolidine antivirals |
US20090324544A1 (en) * | 2008-06-11 | 2009-12-31 | Yao-Ling Qiu | Substituted cyclic pyrrolidine derivatives |
US20100074863A1 (en) * | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
US20100195379A1 (en) * | 2009-02-02 | 2010-08-05 | Qualcomm Incorporated | System and Method of Pulse Generation |
WO2010101967A2 (fr) | 2009-03-04 | 2010-09-10 | Idenix Pharmaceuticals, Inc. | Inhibiteurs de phosphothiophène et phosphothiazole vhc polymérase |
US20100272681A1 (en) * | 2007-02-27 | 2010-10-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of Serine Proteases |
WO2011017389A1 (fr) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Inhibiteurs macrocycliques de la sérine protéase macrocyclique utiles contre les infections virales, en particulier le virus de lhépatite c |
WO2011063076A1 (fr) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Méthodes de traitement du virus de l'hépatite c avec des composés d'oxo-acétamide |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
WO2011075615A1 (fr) | 2009-12-18 | 2011-06-23 | Idenix Pharmaceuticals, Inc. | Inhibiteurs du virus de l'hépatite c à base de 5,5-arylène ou hétéroarylène condensé |
US20110171175A1 (en) * | 2005-08-02 | 2011-07-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
EP2392589A2 (fr) | 2005-11-11 | 2011-12-07 | Vertex Pharmaceuticals Incorporated | Variantes du virus de l'hépatite C |
WO2012109398A1 (fr) | 2011-02-10 | 2012-08-16 | Idenix Pharmaceuticals, Inc. | Inhibiteurs macrocycliques de sérine protéase, compositions pharmaceutiques les contenant et leur utilisation pour le traitement des infections par le vhc |
US8247532B2 (en) | 2006-03-16 | 2012-08-21 | Vertex Pharmaceuticals Incorporated | Deuterated hepatitis C protease inhibitors |
WO2012135581A1 (fr) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Procédés pour traiter une infection par virus de l'hépatite c pharmacorésistant par un inhibiteur de virus de l'hépatite c consistant en arylènes ou hétéroarylènes fusionnés en 5,5 |
US8377962B2 (en) | 2009-04-08 | 2013-02-19 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
US8871904B2 (en) | 2005-08-19 | 2014-10-28 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
WO2015042375A1 (fr) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Inhibiteurs du virus de l'hépatite c |
WO2015134561A1 (fr) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Compositions pharmaceutiques comprenant un inhibiteur de flaviviridae hétéroarylène fusionné en 5,5 et son utilisation pour le traitement ou la prévention d'une infection par les flaviviridae |
WO2015134560A1 (fr) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Formes solides d'un composé inhibiteur des virus de la famille des flaviviridae et sels de celui-ci |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ561851A (en) * | 2002-04-11 | 2009-05-31 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease |
AR045769A1 (es) | 2003-09-18 | 2005-11-09 | Vertex Pharma | Inhibidores de las serina proteasas, particularmente, la proteasa ns3-ns4a del vhc (virus hepatitis c) |
US7569600B2 (en) | 2005-05-13 | 2009-08-04 | Virochem Pharma Inc. | Compounds and methods for the treatment of prevention of Flavivirus infections |
US7456165B2 (en) * | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
CN101489557B (zh) | 2006-02-27 | 2013-12-18 | 弗特克斯药品有限公司 | 包含vx-950的共晶体和包含所述共晶体的药物组合物 |
JP2009530382A (ja) * | 2006-03-23 | 2009-08-27 | シェーリング コーポレイション | Hcvプロテアーゼインヒビターとcyp3a4インヒビターとの組み合わせ、および関連する処置方法 |
EP2559692A1 (fr) | 2006-11-15 | 2013-02-20 | Virochem Pharma Inc. | Analogues du thiophène pour le traitement ou la prévention d'infections par un flavivirus |
KR20090115970A (ko) * | 2007-02-27 | 2009-11-10 | 버텍스 파마슈티칼스 인코포레이티드 | 공-결정 및 그를 포함하는 제약 조성물 |
US8492546B2 (en) | 2007-08-30 | 2013-07-23 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
EP2435424B1 (fr) | 2009-05-29 | 2015-01-21 | Merck Sharp & Dohme Corp. | Composés antiviraux de trois fractions d'aryle liées pour traiter des maladies telles que l'hépatite c |
HUE030402T2 (en) | 2009-09-15 | 2017-05-29 | Taigen Biotechnology Co Ltd | HCV protease inhibitors |
CA2781614A1 (fr) | 2009-11-25 | 2011-06-09 | Vertex Pharmaceuticals Incorporated | Derives d'acide 5-alcynyl-thiophene-2-carboxylique et leur utilisation pour traiter ou prevenir des infections a flavivirus |
WO2011066241A1 (fr) | 2009-11-25 | 2011-06-03 | Schering Corporation | Composés tricycliques fusionnés et leurs dérivés utiles pour le traitement de maladies virales |
CA2785488A1 (fr) | 2009-12-22 | 2011-07-21 | Merck Sharp & Dohme Corp. | Composes tricycliques fusionnes et leurs methodes d'utilisation pour le traitement de maladies virales |
AU2010336355A1 (en) | 2009-12-24 | 2012-07-05 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
PE20130062A1 (es) | 2010-03-09 | 2013-02-28 | Merck Sharp & Dohme | Compuestos de sililo triciclicos fusionados para el tratamiento de enfermedades virales |
CN102869657A (zh) | 2010-03-24 | 2013-01-09 | 沃泰克斯药物股份有限公司 | 用于治疗或预防黄病毒感染的类似物 |
TW201141857A (en) | 2010-03-24 | 2011-12-01 | Vertex Pharma | Analogues for the treatment or prevention of flavivirus infections |
AU2011232348A1 (en) | 2010-03-24 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of Flavivirus infections |
EP2550262A1 (fr) | 2010-03-24 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Analogues destinés au traitement ou à la prévention d'infections à flavivirus |
WO2011156545A1 (fr) | 2010-06-09 | 2011-12-15 | Vertex Pharmaceuticals Incorporated | Modèle dynamique viral pour une polythérapie contre le vhc |
EP2582717A2 (fr) | 2010-06-15 | 2013-04-24 | Vertex Pharmaceuticals Incorporated | Mutants de la protéase ns5b du vhc |
WO2012006070A1 (fr) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Composés et méthodes de traitement ou de prévention d'infections à flavivirus |
MX2012014918A (es) | 2010-06-28 | 2013-04-08 | Vertex Pharma | Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus. |
JP2013531011A (ja) | 2010-06-28 | 2013-08-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染の処置または予防のための化合物および方法 |
WO2012018534A2 (fr) | 2010-07-26 | 2012-02-09 | Schering Corporation | Composés de biphénylène substitué et procédés d'utilisation desdits composés pour le traitement de maladies virales |
CA2808291A1 (fr) | 2010-08-17 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Composes et methodes de traitement ou de prevention d'infections virales par des flaviviridae |
AU2011314168A1 (en) | 2010-09-29 | 2013-04-04 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
US9156872B2 (en) | 2011-04-13 | 2015-10-13 | Merck Sharp & Dohme Corp. | 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
PE20140522A1 (es) | 2011-04-13 | 2014-05-03 | Merck Sharp & Dohme | Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales |
WO2013016501A1 (fr) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Formulations de composés de thiophène |
WO2013016499A1 (fr) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Procédés de préparation de composés du thiophène |
WO2013033899A1 (fr) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Composés benzofuranes substitués et leur procédés d'utilisation pour le traitement de maladies virales |
WO2013033900A1 (fr) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de maladies virales |
WO2013033901A1 (fr) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Dérivés benzofuranes substitués par un hétérocycle et leurs procédés d'utilisation pour le traitement de maladies virales |
WO2013039876A1 (fr) | 2011-09-14 | 2013-03-21 | Merck Sharp & Dohme Corp. | Composés hétérocycliques contenant un silyle et méthodes d'utilisation desdits composés pour traiter les maladies virales |
US20130123276A1 (en) | 2011-11-14 | 2013-05-16 | Sven Ruf | Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases |
US9012427B2 (en) | 2012-03-22 | 2015-04-21 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
KR102161077B1 (ko) * | 2012-06-29 | 2020-09-29 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 반도체 장치 |
WO2014053533A1 (fr) | 2012-10-05 | 2014-04-10 | Sanofi | Utilisation de dérivés substitués de l'acide 3-hétéroaroylamino-propionique en tant que produits pharmaceutiques destinés à la prévention/au traitement de la fibrillation auriculaire |
TW201526899A (zh) | 2013-02-28 | 2015-07-16 | Alios Biopharma Inc | 醫藥組成物 |
WO2015065817A1 (fr) | 2013-10-30 | 2015-05-07 | Merck Sharp & Dohme Corp. | Pseudopolymorphes d'un inhibiteur de la protéine ns5a du vhc et leurs utilisations |
EP3472151A4 (fr) | 2016-06-21 | 2020-03-04 | Orion Ophthalmology LLC | Dérivés de prolinamide carbocycliques |
JP7179721B2 (ja) | 2016-06-21 | 2022-11-29 | オリオン・オフサルモロジー・エルエルシー | 複素環式プロリンアミド誘導体 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US534410A (en) * | 1895-02-19 | Sylvania | ||
US4499082A (en) * | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
US5866684A (en) * | 1996-11-18 | 1999-02-02 | Hoffmann-La Roche Inc. | Peptidyl inhibitors of viral proteases |
US20020123468A1 (en) * | 1999-12-03 | 2002-09-05 | Wei Han | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease |
US20040077600A1 (en) * | 1998-03-31 | 2004-04-22 | Tung Roger D. | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ235155A (en) * | 1989-09-11 | 1993-04-28 | Merrell Dow Pharma | Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical |
WO1992012140A1 (fr) * | 1990-12-28 | 1992-07-23 | Georgia Tech Research Corporation | Cetoamides, cetoacides et cetoesters peptidiques |
US5384410A (en) | 1993-03-24 | 1995-01-24 | The Du Pont Merck Pharmaceutical Company | Removal of boronic acid protecting groups by transesterification |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
UA79749C2 (en) * | 1996-10-18 | 2007-07-25 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
GB9707659D0 (en) * | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
CZ301802B6 (cs) | 1999-03-19 | 2010-06-30 | Vertex Pharmaceuticals Incorporated | Deriváty mocoviny jako inhibitory IMPDH a farmaceutické prostredky s jejich obsahem |
EP1196436A2 (fr) * | 1999-07-07 | 2002-04-17 | Bristol-Myers Squibb Pharma Company | Inhibiteurs de la protease du virus de l'hepatite c a base d'acide boronique peptide |
ATE297946T1 (de) * | 2000-04-03 | 2005-07-15 | Vertex Pharma | Inhibitoren von serin proteasen, speziell der hepatitis-c-virus ns3-protease |
CA2418199A1 (fr) * | 2000-07-21 | 2002-01-31 | Corvas International, Inc. | Nouveaux peptides utilises comme inhibiteurs de ns3-serine protease du virus de l'hepatite c |
PL206255B1 (pl) * | 2000-07-21 | 2010-07-30 | Dendreon Corporationdendreon Corporation | Inhibitor proteazy wirusa zapalenia wątroby C, zawierająca go kompozycja farmaceutyczna i zastosowanie inhibitora do wytwarzania leku do leczenia chorób związanych z HCV oraz zastosowanie do wytwarzania kompozycji do stosowania w kombinowanej terapii |
AR029851A1 (es) * | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
NZ561851A (en) * | 2002-04-11 | 2009-05-31 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease |
-
2004
- 2004-04-09 AT AT04759362T patent/ATE547412T1/de active
- 2004-04-09 EP EP10178023A patent/EP2332935A1/fr not_active Withdrawn
- 2004-04-09 US US10/821,793 patent/US20050090450A1/en not_active Abandoned
- 2004-04-09 WO PCT/US2004/011012 patent/WO2004092162A1/fr active Application Filing
- 2004-04-09 CN CNB2004800140478A patent/CN100453553C/zh not_active Expired - Fee Related
- 2004-04-09 CA CA002521678A patent/CA2521678A1/fr not_active Abandoned
- 2004-04-09 ES ES04759362T patent/ES2381548T3/es not_active Expired - Lifetime
- 2004-04-09 AU AU2004230946A patent/AU2004230946A1/en not_active Abandoned
- 2004-04-09 JP JP2006509873A patent/JP2006526011A/ja active Pending
- 2004-04-09 EP EP04759362A patent/EP1636208B1/fr not_active Expired - Lifetime
- 2004-04-12 AR ARP040101227A patent/AR044513A1/es unknown
-
2006
- 2006-10-18 HK HK06111435.4A patent/HK1090644A1/xx not_active IP Right Cessation
-
2008
- 2008-07-08 US US12/169,209 patent/US20090022688A1/en not_active Abandoned
-
2010
- 2010-10-29 JP JP2010243570A patent/JP2011068655A/ja active Pending
-
2011
- 2011-09-21 US US13/238,386 patent/US8618152B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US534410A (en) * | 1895-02-19 | Sylvania | ||
US4499082A (en) * | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
US5866684A (en) * | 1996-11-18 | 1999-02-02 | Hoffmann-La Roche Inc. | Peptidyl inhibitors of viral proteases |
US20040077600A1 (en) * | 1998-03-31 | 2004-04-22 | Tung Roger D. | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease |
US20020123468A1 (en) * | 1999-12-03 | 2002-09-05 | Wei Han | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease |
Cited By (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090143312A1 (en) * | 1996-10-18 | 2009-06-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
US8314141B2 (en) | 1996-10-18 | 2012-11-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease |
US20030236242A1 (en) * | 2000-04-03 | 2003-12-25 | Robert Perni | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease |
US7494988B2 (en) | 2000-04-03 | 2009-02-24 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease |
US8252923B2 (en) | 2000-08-31 | 2012-08-28 | Vertex Pharmaceuticals Incorporated | Peptidomimetic protease inhibitors |
US20100137583A1 (en) * | 2000-08-31 | 2010-06-03 | Robert Edward Babine | Peptidomimetic protease inhibitors |
US8529882B2 (en) | 2000-08-31 | 2013-09-10 | Vertex Pharmaceuticals Incorporated | Peptidomimetic protease inhibitors |
US20050197299A1 (en) * | 2000-08-31 | 2005-09-08 | Babine Robert E. | Peptidomimetic protease inhibitors |
US7820671B2 (en) | 2000-08-31 | 2010-10-26 | Vertex Pharmaceuticals Incorporated | Peptidomimetic protease inhibitors |
US20060211629A1 (en) * | 2003-07-18 | 2006-09-21 | Britt Shawn D | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US8691758B2 (en) | 2003-07-18 | 2014-04-08 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US8217048B2 (en) | 2003-09-05 | 2012-07-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US7378422B2 (en) * | 2003-09-05 | 2008-05-27 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US20080311079A1 (en) * | 2003-09-05 | 2008-12-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US20050137139A1 (en) * | 2003-09-05 | 2005-06-23 | Perni Robert B. | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US20110104115A1 (en) * | 2003-09-05 | 2011-05-05 | Vertex Pharmaceuticals Incoroprated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
US7745444B2 (en) | 2003-09-05 | 2010-06-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US20070161789A1 (en) * | 2003-10-10 | 2007-07-12 | Cottrell Kevin M | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US7365092B2 (en) | 2003-10-10 | 2008-04-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US8039623B2 (en) | 2003-10-10 | 2011-10-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US20050080017A1 (en) * | 2003-10-10 | 2005-04-14 | Cottrell Kevin M. | Inhibitors of serine proteases, particularly HVC NS3-NS4A protease |
US8536136B2 (en) | 2004-02-04 | 2013-09-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US20100330109A1 (en) * | 2004-02-04 | 2010-12-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
US7683033B2 (en) | 2004-02-04 | 2010-03-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US20050215486A1 (en) * | 2004-02-04 | 2005-09-29 | Kevin Cottrell | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US20110171175A1 (en) * | 2005-08-02 | 2011-07-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
US8871904B2 (en) | 2005-08-19 | 2014-10-28 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
US8372873B2 (en) | 2005-08-26 | 2013-02-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
US20110165120A1 (en) * | 2005-08-26 | 2011-07-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
EP2364984A1 (fr) | 2005-08-26 | 2011-09-14 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de sérine protéases, |
EP2366704A1 (fr) | 2005-08-26 | 2011-09-21 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de sérine protéases, |
US8440706B2 (en) | 2005-08-26 | 2013-05-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
US20110182856A1 (en) * | 2005-08-26 | 2011-07-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
US7985762B2 (en) | 2005-08-26 | 2011-07-26 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
US20070179167A1 (en) * | 2005-08-26 | 2007-08-02 | Cottrell Kevin M | Inhibitors of serine proteases |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
US20070231262A1 (en) * | 2005-11-11 | 2007-10-04 | Vertex Pharmaceuticals, Incorporated | Hepatitis C virus variants |
US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
EP2392589A2 (fr) | 2005-11-11 | 2011-12-07 | Vertex Pharmaceuticals Incorporated | Variantes du virus de l'hépatite C |
US8501450B2 (en) | 2005-11-11 | 2013-08-06 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
EP2392588A2 (fr) | 2005-11-11 | 2011-12-07 | Vertex Pharmaceuticals Incorporated | Variantes du virus de l'hépatite C |
EP2392590A2 (fr) | 2005-11-11 | 2011-12-07 | Vertex Pharmaceuticals Incorporated | Variantes du virus de l'hépatite C |
US8247532B2 (en) | 2006-03-16 | 2012-08-21 | Vertex Pharmaceuticals Incorporated | Deuterated hepatitis C protease inhibitors |
US8575208B2 (en) | 2007-02-27 | 2013-11-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
US20100272681A1 (en) * | 2007-02-27 | 2010-10-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of Serine Proteases |
EP2631238A1 (fr) | 2007-02-27 | 2013-08-28 | Vertex Pharmaceuticals Incorporated | Inhibiteurs spirocycliques de sérine protéases pour le traitement d'infections par le VHC |
WO2009003009A1 (fr) * | 2007-06-26 | 2008-12-31 | Enanta Pharmaceuticals, Inc. | Pyrrolidine substituée utilisée en tant qu'agent anti-infectieux |
US20090022689A1 (en) * | 2007-07-18 | 2009-01-22 | Yat Sun Or | C4-spiro-pyrrolidine antivirals |
US20090060874A1 (en) * | 2007-09-05 | 2009-03-05 | Yao-Ling Qiu | Bicyclic pyrrolidine derivatives |
US20100016578A1 (en) * | 2008-02-04 | 2010-01-21 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
US8093379B2 (en) | 2008-02-04 | 2012-01-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
WO2009099596A2 (fr) | 2008-02-04 | 2009-08-13 | Idenix Pharamaceuticals, Inc. | Inhibiteurs de sérine protéase macrocycliques |
US8003659B2 (en) | 2008-02-04 | 2011-08-23 | Indenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
US20090233972A1 (en) * | 2008-03-12 | 2009-09-17 | Yat Sun Or | Substituted heterocycles as anti-infectives |
US20090326019A1 (en) * | 2008-06-11 | 2009-12-31 | Yat Sun Or | 3,4-bicyclic pyrrolidine antivirals |
US20090324544A1 (en) * | 2008-06-11 | 2009-12-31 | Yao-Ling Qiu | Substituted cyclic pyrrolidine derivatives |
US20100074863A1 (en) * | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
US20100195379A1 (en) * | 2009-02-02 | 2010-08-05 | Qualcomm Incorporated | System and Method of Pulse Generation |
WO2010101967A2 (fr) | 2009-03-04 | 2010-09-10 | Idenix Pharmaceuticals, Inc. | Inhibiteurs de phosphothiophène et phosphothiazole vhc polymérase |
US8377962B2 (en) | 2009-04-08 | 2013-02-19 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
US8993595B2 (en) | 2009-04-08 | 2015-03-31 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
US9284307B2 (en) | 2009-08-05 | 2016-03-15 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors |
WO2011017389A1 (fr) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Inhibiteurs macrocycliques de la sérine protéase macrocyclique utiles contre les infections virales, en particulier le virus de lhépatite c |
WO2011063076A1 (fr) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Méthodes de traitement du virus de l'hépatite c avec des composés d'oxo-acétamide |
WO2011075615A1 (fr) | 2009-12-18 | 2011-06-23 | Idenix Pharmaceuticals, Inc. | Inhibiteurs du virus de l'hépatite c à base de 5,5-arylène ou hétéroarylène condensé |
WO2012109398A1 (fr) | 2011-02-10 | 2012-08-16 | Idenix Pharmaceuticals, Inc. | Inhibiteurs macrocycliques de sérine protéase, compositions pharmaceutiques les contenant et leur utilisation pour le traitement des infections par le vhc |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
WO2012135581A1 (fr) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Procédés pour traiter une infection par virus de l'hépatite c pharmacorésistant par un inhibiteur de virus de l'hépatite c consistant en arylènes ou hétéroarylènes fusionnés en 5,5 |
WO2015042375A1 (fr) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Inhibiteurs du virus de l'hépatite c |
WO2015134561A1 (fr) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Compositions pharmaceutiques comprenant un inhibiteur de flaviviridae hétéroarylène fusionné en 5,5 et son utilisation pour le traitement ou la prévention d'une infection par les flaviviridae |
WO2015134560A1 (fr) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Formes solides d'un composé inhibiteur des virus de la famille des flaviviridae et sels de celui-ci |
Also Published As
Publication number | Publication date |
---|---|
JP2011068655A (ja) | 2011-04-07 |
CA2521678A1 (fr) | 2004-10-28 |
ATE547412T1 (de) | 2012-03-15 |
EP2332935A1 (fr) | 2011-06-15 |
US20120014914A1 (en) | 2012-01-19 |
EP1636208A1 (fr) | 2006-03-22 |
AU2004230946A1 (en) | 2004-10-28 |
HK1090644A1 (en) | 2006-12-29 |
US20090022688A1 (en) | 2009-01-22 |
CN100453553C (zh) | 2009-01-21 |
WO2004092162A1 (fr) | 2004-10-28 |
AR044513A1 (es) | 2005-09-14 |
CN1795188A (zh) | 2006-06-28 |
US8618152B2 (en) | 2013-12-31 |
EP1636208B1 (fr) | 2012-02-29 |
ES2381548T3 (es) | 2012-05-29 |
JP2006526011A (ja) | 2006-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8618152B2 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | |
US8691758B2 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
US7906550B2 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
US7273885B2 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
US7378422B2 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
JP4685775B2 (ja) | セリンプロテアーゼ、とりわけhcvns3−ns4aプロテアーゼの阻害剤 | |
US20050137140A1 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | |
WO2005007681A9 (fr) | Inhibiteurs de serines proteases, en particulier de la protease ns3-ns4a du vhc | |
AU2011203054B2 (en) | Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: VERTEX PHARMACEUTICALS, INCORPORATED, MASSACHUSETT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FARMER, LUC J.;PERNI, ROBERT B.;BHISETTI, GOVINDA RAO;AND OTHERS;REEL/FRAME:015091/0001;SIGNING DATES FROM 20040628 TO 20040706 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |